NGM · Drug Manufacturers - Specialty & Generic
AQST (AQST) Stock
$3.60
-4.26%
NGM: AQST
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
GlobeNewswire · Jul 7, 2026
Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last?
Zacks · Jun 24, 2026
Does US manufacturing give drugmakers a speed edge?
Pharma Voice · Jun 23, 2026
The Aquestive Therapeutics, Inc. (NASDAQ:AQST) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Simply Wall St. · May 15, 2026
Aquestive Therapeutics Inc (AQST) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...
GuruFocus.com · May 14, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held3.10%
Institutions Held58.83%
Institutions Float Held60.71%
Peer Comparison
About AQST
AQST is led by CEO Daniel Barber, employs 142 people, headquartered in US, publicly traded since 2018.
AQST stock trades at $3.60 with a market capitalization of $451.68M. The stock is valued at a price-to-earnings (P/E) ratio of -6.11, price-to-book of -13.43, price-to-sales of 9.31. Over the past 52 weeks the stock has ranged between $2.93 and $7.55, and currently trades 52.3% below its 52-week high.
On profitability, AQST generates a return on equity (ROE) of 190.87% — well above the market average, a sign of a high-quality business, return on capital employed of -51.10%, an operating margin of -155.56%, a net profit margin of -137.08%.